Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
A phase 2 trial of Lutetium-177 dotatate in pheochromocytoma and paraganglioma, run by Advanced Accelerator Applications, active and no longer recruiting.
Overview
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs is a phase 2 interventional study registered as NCT04711135 by Advanced Accelerator Applications, with 11 participants enrolled, started 2022-08-31 and due to reach its primary completion in 2024-03-12. Interventions recorded: Lutetium [177Lu] oxodotreotide/dotatate. Conditions listed: Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Shares Lutetium-177 dotatate, Novartis.
- IdeaBuild Western ytterbium-176 enrichment so lutetium-177 has more than one supplier
Shares Lutetium-177 dotatate, Novartis.
- TechnologySomatostatin receptor PET (68Ga/64Cu-DOTATATE)
Shares Pheochromocytoma and paraganglioma (PPGL), Lutetium-177 dotatate.
- Key paperNETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours
Shares Lutetium-177 dotatate, Novartis.
- TechnologyPeptide receptor radionuclide therapy (PRRT)
Shares Pheochromocytoma and paraganglioma (PPGL), Lutetium-177 dotatate, Novartis.
- InstitutionErasmus MC Cancer Institute
Shares Lutetium-177 dotatate, Novartis.
- CancerMultiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)
Shares Pheochromocytoma and paraganglioma (PPGL), Lutetium-177 dotatate.